Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has described antibody-drug conjugates (ADCs) comprising antibodies targeting cadherin-3 (CDH3; CDHP; P-cadherin) covalently linked to cytotoxic drug through a linker. They are reported to be useful for the treatment of cancer.
The pressure to replace animal testing with human-relevant assays that are more predictive of human-drug responses has now reached a tipping point, and there is a movement toward greater acceptance of these potentially more translatable tests.
Kunshan Xinyunda Biotechnology Co. Ltd. has discovered antibody-drug conjugates (ADCs) consisting of antibodies covalently linked to cytotoxic drugs potentially useful for the treatment of cancer.
